Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian CancerFormulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
/in Glioblastoma, International Publications, IOZK VeröffentlichungenOncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusBispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusIntegration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenTV-Beitrag-National Institutes of Health: Will Dendritic Cell Subsets help us address the challenges of Cancer, Autoimmunity and Viral Diseases?
/in Externe MeldungenAnalysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusNewcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer